Adverse Cardiovascular Events Temporally Associated With Ma
... of the 37 patients. A review of clinical records and investigative interviews indicates that 36 of the patients used ma huang according to the manufacturers’ recommendations. A 20-year-old man died suddenly after ingesting 2 times the manufacturer’s recommended dosage. No patient had a clinical hist ...
... of the 37 patients. A review of clinical records and investigative interviews indicates that 36 of the patients used ma huang according to the manufacturers’ recommendations. A 20-year-old man died suddenly after ingesting 2 times the manufacturer’s recommended dosage. No patient had a clinical hist ...
New Anticoagulants For Stroke Prevention in AF Atrial Fibrillation
... ● The NOACs offer better efficacy, safety, and convenience compared with OACS with VKAs. Thus, where and OAC is recommended, one of the NOACs – either a direct thrombin inhibitor (dabigatran) or an active factor Xa inhibitor (e.g. rivaroxaban, apixaban) – should be considered instead of adjusted-dos ...
... ● The NOACs offer better efficacy, safety, and convenience compared with OACS with VKAs. Thus, where and OAC is recommended, one of the NOACs – either a direct thrombin inhibitor (dabigatran) or an active factor Xa inhibitor (e.g. rivaroxaban, apixaban) – should be considered instead of adjusted-dos ...
SERIES ‘‘PULMONARY HYPERTENSION: BASIC CONCEPTS FOR PRACTICAL MANAGEMENT’’
... VolibrisTM: GlaxoSmithKline, London, UK, in other parts of the world). This drug is also presented as a selective ETAR blocker, although many of its published ETA:ETB affinity ratios display an ETA:ETB selectivity of about one log, slightly higher than that of bosentan [35]. Based on pre-clinical da ...
... VolibrisTM: GlaxoSmithKline, London, UK, in other parts of the world). This drug is also presented as a selective ETAR blocker, although many of its published ETA:ETB affinity ratios display an ETA:ETB selectivity of about one log, slightly higher than that of bosentan [35]. Based on pre-clinical da ...
Myofascial Pain: An Open Study on the Pharmacotherapeutic
... Consistent with the protocol used in the authors’ clinic, a stepped pharmacotherapeutic approach was used. Patients diagnosed with MFP with referral were started on amitriptyline 10 mg daily at bedtime and their status was reviewed at 2 weeks. At this or any time during treatment, patients with clin ...
... Consistent with the protocol used in the authors’ clinic, a stepped pharmacotherapeutic approach was used. Patients diagnosed with MFP with referral were started on amitriptyline 10 mg daily at bedtime and their status was reviewed at 2 weeks. At this or any time during treatment, patients with clin ...
Card_dyslipidemia diabetes2 ER.indd
... In addition to being the most common lipid abnormality in type 2 diabetes mellitus, hypertriglyceridaemia is also a feature of impaired glucose tolerance and impaired fasting glucose. The purpose of this quick reference guide is to offer proper information and guidance to primary health care physici ...
... In addition to being the most common lipid abnormality in type 2 diabetes mellitus, hypertriglyceridaemia is also a feature of impaired glucose tolerance and impaired fasting glucose. The purpose of this quick reference guide is to offer proper information and guidance to primary health care physici ...
M10-240 - AbbVie
... Adalimumab concentrations were to be summarized at each time point using descriptive statistics. Individual subject concentration vs time plots and mean concentration vs time plots were to be provided. Population pharmacokinetics analysis was to be performed to estimate adalimumab apparent clearance ...
... Adalimumab concentrations were to be summarized at each time point using descriptive statistics. Individual subject concentration vs time plots and mean concentration vs time plots were to be provided. Population pharmacokinetics analysis was to be performed to estimate adalimumab apparent clearance ...
5.01.522 Advanced Therapies for Pharmacological Treatment of
... ventricular dilation and low cardiac output. Premature death commonly results from right heart failure. Idiopathic IPAH is the most common type of PAH and is more prevalent in women than in men. Familial PAH often results from a mutation in bone morphogenetic protein receptor-2 (BMPR2) and is inheri ...
... ventricular dilation and low cardiac output. Premature death commonly results from right heart failure. Idiopathic IPAH is the most common type of PAH and is more prevalent in women than in men. Familial PAH often results from a mutation in bone morphogenetic protein receptor-2 (BMPR2) and is inheri ...
Overcoming toxicity and side-effects of lipid
... was not significant [15]. Therefore, there is evidence to support an association between statin use and an increased incidence of diabetes mellitus. Interestingly, there could be varying levels of risk depending on the statin used. Recent guidelines from the ACC/AHA conclude that an increased risk fo ...
... was not significant [15]. Therefore, there is evidence to support an association between statin use and an increased incidence of diabetes mellitus. Interestingly, there could be varying levels of risk depending on the statin used. Recent guidelines from the ACC/AHA conclude that an increased risk fo ...
Cytochrome P450 Genotyping
... pronounced for stent thrombosis in patients undergoing percutaneous coronary intervention. The evidence addressing whether the use of CYP2C19 genotype-directed therapy improves outcomes is limited. One RCT comparing CYP2C19 genotype-directed antiplatelet therapy reported that patients receiving geno ...
... pronounced for stent thrombosis in patients undergoing percutaneous coronary intervention. The evidence addressing whether the use of CYP2C19 genotype-directed therapy improves outcomes is limited. One RCT comparing CYP2C19 genotype-directed antiplatelet therapy reported that patients receiving geno ...
III. Non-clinical aspects
... bioequivalence studies, one of which did not demonstrate bioequivalence. Insufficiently justified exclusions of subjects (study BCD-P5.010) based on PK data strongly suggest, that the truth results lie even more far away from the bioequivalence range than the data presented. The time of exclusion of ...
... bioequivalence studies, one of which did not demonstrate bioequivalence. Insufficiently justified exclusions of subjects (study BCD-P5.010) based on PK data strongly suggest, that the truth results lie even more far away from the bioequivalence range than the data presented. The time of exclusion of ...
ORGANIC VOLATILE IMPURITIES AND THEIR REGULATORY LIMITS ( AS A PART OF PREFORMULATION)
... level, the drug product should be tested to ascertain whether the formulation process has ...
... level, the drug product should be tested to ascertain whether the formulation process has ...
Sunday 22nd December: PSA1
... These data indicate that although there has been a significant increase in oxygenation she is experiencing a significant increase in CO2 retention while breathing 28% oxygen, which has reduced her hypoxic respiratory drive and might depress her conscious level. Option B Justification She requires so ...
... These data indicate that although there has been a significant increase in oxygenation she is experiencing a significant increase in CO2 retention while breathing 28% oxygen, which has reduced her hypoxic respiratory drive and might depress her conscious level. Option B Justification She requires so ...
pharmacokinetics of 7-day multiple-dose tedizolid
... for physicians as outcome may be associated with increased mortality.1 There is a high unmet medical need in the management of such infections because the existing effective antibiotics often need monitoring of their therapeutic level and require dose adjustment in special populations (e.g. elderly, ...
... for physicians as outcome may be associated with increased mortality.1 There is a high unmet medical need in the management of such infections because the existing effective antibiotics often need monitoring of their therapeutic level and require dose adjustment in special populations (e.g. elderly, ...
Comparison of pre-emptive effeCt of meloxiCam and CeleCoxCib on post-operative analgesia:
... human and animals18,19. Meloxicam and robenacoxib, which have similar pharmacologic profiles, have been used in veterinary medicine to reduce pain in cats, and robenacoxib has been shown to be more effective20. The aim of the current study is to compare the preoperative analgesic effects of meloxica ...
... human and animals18,19. Meloxicam and robenacoxib, which have similar pharmacologic profiles, have been used in veterinary medicine to reduce pain in cats, and robenacoxib has been shown to be more effective20. The aim of the current study is to compare the preoperative analgesic effects of meloxica ...
AusPAR: Regorafenib
... Regorafenib is a new chemical entity which inhibits multiple kinases that are involved in tumour growth, as well as in a wide range of normal cellular functions. Regorafenib and its two major circulating metabolites in humans, M-2 (N-oxide metabolite) and M-5 (N-oxide and N-desmethyl metabolite), we ...
... Regorafenib is a new chemical entity which inhibits multiple kinases that are involved in tumour growth, as well as in a wide range of normal cellular functions. Regorafenib and its two major circulating metabolites in humans, M-2 (N-oxide metabolite) and M-5 (N-oxide and N-desmethyl metabolite), we ...
Senior Scientist Computational Biology - Pharma
... In June 2006, the FDA approved REVLIMID in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID is only available through a restricted distribution program called RevAssist ®. EMEA approval for the REVLIMID® multiple mye ...
... In June 2006, the FDA approved REVLIMID in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID is only available through a restricted distribution program called RevAssist ®. EMEA approval for the REVLIMID® multiple mye ...
PRODUCT INFORMATION ZOLOFT (sertraline hydrochloride) NAME OF THE MEDICINE
... demonstrated a significantly lower relapse rate over the next eight weeks for patients taking ZOLOFT compared to those on placebo. Therefore, the physician who elects to use ZOLOFT for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. O ...
... demonstrated a significantly lower relapse rate over the next eight weeks for patients taking ZOLOFT compared to those on placebo. Therefore, the physician who elects to use ZOLOFT for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. O ...
Comparison of antiepileptic drug prescribing in children in three
... type (conventional vs. newer AEDs). We also analyzed the frequency of AEDs prescribed for children and adolescents with an indication/diagnosis of epilepsy for all three databases together. Due to the absence of adolescent data in PEDIANET, prevalence of AED use for comparison in three countries was ...
... type (conventional vs. newer AEDs). We also analyzed the frequency of AEDs prescribed for children and adolescents with an indication/diagnosis of epilepsy for all three databases together. Due to the absence of adolescent data in PEDIANET, prevalence of AED use for comparison in three countries was ...
Buprenorphine: A New Alternative in the Treatment of Opioid Addiction
... Treatment of addiction disorders are a long term and complicated process requiring additional training and familiarity with addiction disorders and with common comorbid psychiatric disorders. In the United States physicians who are interested in using buprenorphine for opioid detoxification and ma ...
... Treatment of addiction disorders are a long term and complicated process requiring additional training and familiarity with addiction disorders and with common comorbid psychiatric disorders. In the United States physicians who are interested in using buprenorphine for opioid detoxification and ma ...
Prescribing Information
... In the two U.S. studies, symptomatic postural hypotension was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and by no patients in the placebo group. Syncope was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patien ...
... In the two U.S. studies, symptomatic postural hypotension was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and by no patients in the placebo group. Syncope was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patien ...
Anyanwu, Philip, Fulton, John, Paget, Timothy and Evans, Etta (2016
... relation to antimalarial drug use behaviours. These socioeconomic actors were categorized into Educational level (10 studies); Level of income/wealth (6 studies); Type of settlement (3 studies); Ability to read (2 studies); Occupation/Source of income (2 studies); and Household size (1 study). These ...
... relation to antimalarial drug use behaviours. These socioeconomic actors were categorized into Educational level (10 studies); Level of income/wealth (6 studies); Type of settlement (3 studies); Ability to read (2 studies); Occupation/Source of income (2 studies); and Household size (1 study). These ...
Jatinder Harchowal - hpe-live
... The aim of the national cancer vanguard programme is to tackle three gaps: ...
... The aim of the national cancer vanguard programme is to tackle three gaps: ...
LSD is a powerful hallucinogen. It has short and long term
... LSD LSD is a powerful hallucinogen. It has short and long term effects. It’s possible to have a “bad trip” where the experience is negative and traumatic. There are things you can do if you or someone else has a bad trip. There are other issues with LSD as well. What’s LSD? LSD is a chemical that c ...
... LSD LSD is a powerful hallucinogen. It has short and long term effects. It’s possible to have a “bad trip” where the experience is negative and traumatic. There are things you can do if you or someone else has a bad trip. There are other issues with LSD as well. What’s LSD? LSD is a chemical that c ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.